Candel Therapeutics (CADL) Other Non-Current Liabilities (2020 - 2025)

Candel Therapeutics has disclosed Other Non-Current Liabilities across 6 years of filings, most recently posting $15.6 million for Q4 2025.

• Other Non-Current Liabilities for Q4 2025 came in at $15.6 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $15.6 million (changed N/A YoY), and the FY2025 annual result was $15.6 million, changed N/A from the prior year.
• Other Non-Current Liabilities came in at $15.6 million for Q4 2025 at Candel Therapeutics, down from $15.9 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $27.4 million in Q3 2021 to a low of $433000.0 in Q3 2023.
• The 5-year median for Other Non-Current Liabilities is $5.0 million (2022), against an average of $9.1 million.
• Across the five-year window, Other Non-Current Liabilities slumped 90.64% in 2023 and jumped 3568.82% in 2024, its largest moves.
• Candel Therapeutics' Other Non-Current Liabilities stood at $18.3 million in 2021, then plunged by 89.69% to $1.9 million in 2022, then sank by 51.33% to $916000.0 in 2023, then surged by 1634.28% to $15.9 million in 2024, then decreased by 1.81% to $15.6 million in 2025.
• The last three Other Non-Current Liabilities figures came in at $15.6 million (Q4 2025), $15.9 million (Q3 2024), and $14.2 million (Q2 2024), per Business Quant data.